Asia-Pacific Monoclonal Antibodies market report delivers a basic overview of the industry including its applications and manufacturing cost, revenue, etc.
The Asia-Pacific Cancer Monoclonal Antibodies Market is currently valued at USD 4.32 billion in 2015 and is forecasted to be a USD 8.14 Billion market by 2020 with a tremendous growth rate of 13.5%. Cancer is the leading cause of death across the globe currently. It starts from a single cell in the body genetically transforming a normal cell to a tumour and is eventually spread to other cells. Typically, drugs and chemotherapy are used as a treatment to cure cancer. The adverse side effects that comes with them has made the pharmaceutical companies to concentrate on Cancer Monoclonal Antibodies.
Browse a Report@ http://www.orbisresearch.com/reports/index/asia-pacific-cancer-monoclonal-antibodies-market-by-application-by-type-by-conjugated-cancer-therapies-and-by-region-global-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021
Cancer Monoclonal Antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat the disease. Recent years have seen the emergence of Cancer Monoclonal Antibodies being used to treat wide array of diseases that are related to cancer. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus Cancer Monoclonal Antibodies due to its customizable nature can be used to treat the cancerous cells not effecting the normal ones.
With the increase in the cases of cancer in the recent past, the pharmaceutical companies has started investing aggressively in Cancer Monoclonal Antibodies. The primary drivers for the market include increased investment in R&D for genomic studies, specificity to target only the cancer cell by Cancer Monoclonal Antibodies and technological evolvement in genetic sequencing and target gene selection. However, high costs of development, longer durations required for clinical trials and research & development of antibodies are a few factors to overcome in order for the market to evolve.
Request a sample copy of Report @ http://www.orbisresearch.com/contacts/request-sample/313433
The Asia-Pacific Cancer Monoclonal Antibodies Market are divided based on its application as Breast, liver, Brain, Blood, colorectal, leukaemia, Hodgkins & Non-Hodgkins and others. The market is further analysed on the basis of type as fully humanized antibodies, murine antibodies and chimeric & humanised antibodies. The market based on Conjugated Cancer therapies is segmented as Immunocytokines, ADEPT, Radioimmunotherapy and Immunoliposome. The market based on the geography of Asia-Pacific is segmented as China, India, Japan, South Korea and others.
The key players of the market are Amgen, Bristol Myers Squibb, Eli Lilly, Roche, Immunogen, Novartis, Glaxosmithkline, Genmab, Seattle Genetics and Spectrum Pharaceuticals.
Major Points from Table of Contents
4.Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
8.Market Leaders’ Analysis
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: [email protected]